S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
3 Value Stocks Too Small For Buffett’s Portfolio
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
3 Value Stocks Too Small For Buffett’s Portfolio
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
3 Value Stocks Too Small For Buffett’s Portfolio
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
3 Value Stocks Too Small For Buffett’s Portfolio
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:NBRV

Nabriva Therapeutics (NBRV) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
$0.00
$0.52
52-Week Range
N/A
Volume
N/A
Average Volume
29,344 shs
Market Capitalization
$45.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
NBRV stock logo

About Nabriva Therapeutics Stock (NASDAQ:NBRV)

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

NBRV Stock News Headlines

Nabriva Therapeutics (NASDAQ:NBRV) Now Covered by StockNews.com
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
NBRV - Nabriva Therapeutics plc
NBRV Nabriva Therapeutics plc
Nabriva Therapeutics Provides Corporate Update
Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
Nabriva's stock is up after sharing antibiotic news
See More Headlines
Receive NBRV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nabriva Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/06/2021
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NBRV
Employees
39
Year Founded
N/A

Profitability

Net Income
$-57,190,000.00
Net Margins
-148.11%
Pretax Margin
-144.78%

Debt

Sales & Book Value

Annual Sales
$35.59 million
Book Value
$0.10 per share

Miscellaneous

Free Float
31,493,000
Market Cap
$45.46 million
Optionable
Not Optionable
Beta
1.53
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

NBRV Stock Analysis - Frequently Asked Questions

How were Nabriva Therapeutics' earnings last quarter?

Nabriva Therapeutics plc (NASDAQ:NBRV) issued its quarterly earnings results on Thursday, May, 6th. The biotechnology company reported ($13.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($16.75) by $3.50. The biotechnology company earned $2.53 million during the quarter, compared to analyst estimates of $2.25 million. Nabriva Therapeutics had a negative net margin of 148.11% and a negative trailing twelve-month return on equity of 365.53%.
Read the conference call transcript
.

When did Nabriva Therapeutics' stock split?

Shares of Nabriva Therapeutics reverse split on Friday, September 16th 2022. The 1-25 reverse split was announced on Friday, September 16th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 16th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Nabriva Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nabriva Therapeutics investors own include SCYNEXIS (SCYX), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Dynavax Technologies (DVAX), Acasti Pharma (ACST), Amarin (AMRN), AcelRx Pharmaceuticals (ACRX), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and Heat Biologics (HTBX).

How do I buy shares of Nabriva Therapeutics?

Shares of NBRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NBRV) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners